Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12609000228280
Ethics application status
Approved
Date submitted
9/05/2008
Date registered
8/05/2009
Date last updated
8/05/2009
Type of registration
Retrospectively registered

Titles & IDs
Public title
Randomised Controlled Trial of Cognitive Behaviour Therapy for Reduction in Posttraumatic Stress Disorder (PTSD) Symptoms
Scientific title
Randomised Controlled Trial of Cognitive Behaviour Therapy for Reduction in Posttraumatic Stress Disorder (PTSD) Symptoms After Exposure to Any Traumatic Event
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Posttraumatic Stress Disorder 3132 0
Condition category
Condition code
Mental Health 3295 3295 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Modified Cognitive Behaviour Therapy involves 12 once-weekly 90-minute sessions of individual therapy over 12 weeks. The therapy includes brief reliving of trauma memories (5 minute duration) integrated with re-appraisals of beliefs of the trauma experience. The duration of the study for any participant will conclude after the 6-month follow-up assessment, resulting in participation duration of 9 months.
Intervention code [1] 2874 0
Treatment: Other
Comparator / control treatment
Cognitive Behaviour Therapy involves 12 once-weekly 90-minute sessions of individual therapy over 12 weeks. The therapy includes prolonged reliving of trauma memories (40 minute duration) integrated with re-appraisals of beliefs of the trauma experience. The duration of the study for any patient will conclude after the 6-month follow-up assessment, resulting in participation duration of 9 months.
Control group
Active

Outcomes
Primary outcome [1] 4183 0
Posttraumatic stress disorder as measured by the Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale
Timepoint [1] 4183 0
Pretreatment, Posttreatment, 6-Month Follow-Up
Secondary outcome [1] 7067 0
Depression as measured by the Beck Depression Inventory
Timepoint [1] 7067 0
Pretreatment, Posttreatment, 6-Month Follow-Up

Eligibility
Key inclusion criteria
(1) Exposure to trauma, (2) Meet criteria for PTSD
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Suicidal intent, psychotic, substance dependent

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be treatment seeking patients attending the Traumatic Stress Clinic at Westmead Hospital. Participants will be randomly assigned according to a random numbers system administered by an individual who is independent of the study and who works at a site that is distant from the treatment center.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomization will be conducted by a process of minimization stratified on gender, trauma type, and Posttraumatic Stress Disorder severity.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/06/2008
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
70
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 3371 0
Government body
Name [1] 3371 0
National Health & Medical Research Council
Country [1] 3371 0
Australia
Primary sponsor type
University
Name
University of New South Wales
Address
University of New South Wales
Sydney, NSW, 2052
Country
Australia
Secondary sponsor category [1] 3016 0
Hospital
Name [1] 3016 0
Westmead Hospital
Address [1] 3016 0
Westmead Hospital
O'Briens Road
Westmead, NSW, 2145
Country [1] 3016 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 5395 0
Sydney West Area Health Service Human Ethics Committee
Ethics committee address [1] 5395 0
Ethics committee country [1] 5395 0
Australia
Date submitted for ethics approval [1] 5395 0
Approval date [1] 5395 0
12/02/2007
Ethics approval number [1] 5395 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 28580 0
Address 28580 0
Country 28580 0
Phone 28580 0
Fax 28580 0
Email 28580 0
Contact person for public queries
Name 11737 0
Professor Richard Bryant
Address 11737 0
School of Psychology
University of New South Wales
Sydney, NSW, 2052
Country 11737 0
Australia
Phone 11737 0
61-2-93853640
Fax 11737 0
61-2-93853641
Email 11737 0
[email protected]
Contact person for scientific queries
Name 2665 0
Professor Richard Bryant
Address 2665 0
School of Psychology
University of New South Wales
Sydney, NSW, 2052
Country 2665 0
Australia
Phone 2665 0
61-2-93853640
Fax 2665 0
61-2-93853641
Email 2665 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.